+315.5%
ARM vs MRNA
+24.9%
+290.6%
-54.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.0% | -3.4% | +4.4% | +1.2% |
| 7D | +12.5% | -10.1% | +22.6% | +13.2% |
| 30D | -1.4% | +126.7% | -128.1% | -12.4% |
| 3M | -18.7% | +184.1% | -202.8% | -32.2% |
| 6M | +124.6% | +143.3% | -18.7% | +93.2% |
| YTD | +141.7% | +359.9% | -218.1% | +78.3% |
| 1Y | +87.7% | +454.2% | -366.5% | +30.6% |
| All | +315.5% | +24.9% | +290.6% | +248.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling